दवाओं की अंतःक्रिया
Concizumab + Factor viii
गंभीरता: गंभीर
Concizumab and Factor viii: major interaction.
अंतिम अपडेट
केवल स्वास्थ्य पेशेवरों के लिए — मात्र संदर्भ हेतु। यह पृष्ठ संक्षिप्त सारांश है, चिकित्सकीय सलाह नहीं है और आधिकारिक लेबल या नैदानिक निर्णय का विकल्प नहीं है। दवा लिखने या देने से पहले हमेशा जाँच करें।
इस पृष्ठ की नैदानिक सामग्री केवल अंग्रेज़ी में उपलब्ध है।
सारांश
Concizumab reduces bleeding by inhibiting tissue factor pathway inhibitor, so added factor VIII at high or frequent doses can increase thrombotic risk. Thromboembolic events have been reported with concomitant breakthrough-bleed treatment.
इस इंटरैक्शन का सरल भाषा में अर्थ
Concizumab and Factor viii can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Concizumab belongs to Miscellaneous; Factor viii belongs to Cardiovascular.
ऐसा क्यों होता है
Additive procoagulant effects of TFPI inhibition and exogenous factor replacement.
क्या करें
Treat breakthrough bleeds with the lowest approved factor VIII dose that achieves hemostasis. Monitor for signs of thrombosis.
फार्मासिस्ट से क्या पूछें
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ सदस्यों के लिए
पूरा पेज खोलें
Concizumab और Factor viii की पूरी प्रबंधन सलाह, अतिरिक्त नोट्स, साक्ष्य का विवरण और पूरे पर्चे का इंटरैक्शन चेकर खोलने के लिए खाता बनाएँ और Pro+ ट्रायल शुरू करें।
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
वेब पर Pro+ को 14 दिन मुफ़्त आज़माएँ। कार्ड की ज़रूरत नहीं।
Concizumab के अन्य इंटरैक्शन
- Concizumab + Factor ix गंभीर
Factor viii के अन्य इंटरैक्शन
अक्सर पूछे जाने वाले प्रश्न
Can I take Concizumab with Factor viii?
MediHelp rates the interaction as major. Concizumab and Factor viii can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Concizumab reduces bleeding by inhibiting tissue factor pathway inhibitor, so added factor VIII at high or frequent doses can increase thrombotic risk. Thromboembolic events have been reported with concomitant breakthrough-bleed treatment.
How serious is the interaction between Concizumab and Factor viii?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Treat breakthrough bleeds with the lowest approved factor VIII dose that achieves hemostasis. Monitor for signs of thrombosis.
What other medicines interact with Concizumab?
MediHelp also lists interactions of Concizumab with, for example, Factor ix. The full list is on the Concizumab page.
MediHelp ऐप में पूर्ण मोनोग्राफ़, खुराक और इंटरैक्शन चेकर
MediHelp ऐप में पूरा संदर्भ खोलें, कई दवाओं की अंतःक्रियाएँ जाँचें और खुराक टूल इस्तेमाल करें।
